Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Nuclear Medicine Radioisotopes Market?

The market size of nuclear medicine radioisotopes has experienced considerable growth in recent years. Its size is projected to increase from $8.21 billion in 2024 to $8.85 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. The factors driving the growth in the past were associated with the discovery of radioactivity, the emergence of nuclear medicine, therapeutic applications, clinical research, and increased patient demand.

Significant surges are anticipated in the nuclear medicine radioisotopes market size over the coming years, with projections pegging it at $11.96 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%. This forecasted growth can be ascribed to factors such as enhanced healthcare expenditure, advancement of healthcare facilities, heightened awareness towards environmental sustainability, educational drives and awareness initiatives, and growth in medical tourism. Furthermore, emerging trends during this forecast period encompass the creation of new radioisotopes, innovations within production and supply chain, microfluidics and lab-on-a-chip technology, incorporation of artificial intelligence in radiopharmaceutical development, and nanotechnology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Nuclear Medicine Radioisotopes Market?

The growth of the nuclear medicine radioisotope market is predicted to be fueled by the increasing instances of cardiovascular diseases. A term denoting a cluster of diseases affecting the heart and blood vessels, cardiovascular diseases have seen a surge due to factors such as a sedentary lifestyle, poor eating habits, increased obesity rates, and aging demographics. Radioisotopes in nuclear medicine play a critical role in diagnosing and managing cardiovascular diseases by providing detailed information about cardiac function, perfusion, and tissue viability, which are crucial for precise diagnosis and effective treatment planning. For instance, stats published by the British Heart Foundation, a cardiovascular research charity based in the UK, revealed that 7.6 million people, comprised of 4 million men and 3.6 million women, battled heart and circulatory diseases in the UK, as of September 2024. These conditions were the culprit behind around 27% of all UK deaths, equivalent to over 170,000 deaths every year, or about 480 daily deaths. This translates to one person dying every three minutes. Hence, the growth of the nuclear medicine radioisotope market can be associated with the rising instances of cardiovascular diseases.

What Are The Main Segment Classifications In The Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market covered in this report is segmented –

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types

2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications

3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Subsegments:

1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)

2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging

3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)

4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging

5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging

6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment

7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment

8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo)

9) By Alpharadin (Radium-223 Alpha Emitters): Alpharadin For Bone Metastasis Treatment

10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

How Are Industry Trends Steering The Expansion Of The Nuclear Medicine Radioisotopes Market?

The focus of leading businesses in the nuclear medicine radioisotopes market is on the creation of innovative products like the compact low-energy cyclotron for enhancing radioisotope production and availability, thereby ensuring more effective, readily available diagnostic and therapeutic solutions. A compact low-energy cyclone, a mini particle accelerator, is employed for the creation of radioisotopes useful in medical imaging and nuclear medicine treatments. To exemplify, IBA, a radiopharmaceutical production solutions provider hailing from Belgium, introduced Cyclone Key, a new accelerator, in January 2022 to broaden the reach of diagnostic alternatives and facilitate in-house radiopharmaceutical production. The innovative solution boasts unique attributes such as a compact, efficient structure, fully programmed operation, the ability to produce multiple isotopes, installation and operation convenience, water cooling, self-protection, and high performance, bringing about versatility and dependability.

Which Firms Are Driving Innovation Within The Nuclear Medicine Radioisotopes Market?

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacibasi-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

What Are The Emerging Regional Trends Driving The Nuclear Medicine Radioisotopes Market?

North America was the largest region in the nuclear medicine radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16132&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model